Table 3.
Characteristics of the type 1 diabetic patients from the French pharmaco vigilance database
| Variables | Characteristics (n = 14) |
|---|---|
| Sex M/F (n) | 7/7 |
| Age (median) (years) | 69 (range 40–82) |
| BMI (kg/m2) (median) | 24.1 (range 17.6–28.3)/data unknown for 3 patients |
| Cardiovascular risk factors | n = 14 |
| Dyslipidemia | 2 |
| Hypertension | 3 |
| Type 2 diabetes | 1 |
| Obesity | 1 |
| Type of cancer (n) | |
| Melanoma | 8 |
| Lung cancer | 5 |
| Clear renal cell carcinoma | 1 |
| Prior autoimmune disease (n) | 4 patients |
| Thyroiditis | 4 |
| Rheumatoid arthritis | 1 |
| Psoriasis | 1 |
| Treatment (n) | |
| Ipilimumab | 4 |
| Pembrolizumab | 1 |
| Nivolumab | 9 |
| Other immune-related concomitant side effects (n) | |
| Colitis | 2 |
| Hepatitis | 1 |
| Thrombopenia | 1 |
| Pneumonitis | 1 |
| Thyroiditis | 2 |
| Time to onset (weeks) | 8 (range 1.7–63) |
| Symptoms at diagnosis | |
| Polyuria polydispia | 8 |
| Asthenia | 6 |
| Anorexia/weight loss | 6 |
| Neurological disorders | 4 |
| Abdominal disorders | 7 |
| Tachypnea | 2 |
| Ketoacidosis at diagnosis | 12 (N/A data for 2 patients) |
| Glycemia (median) (mmol/l) | 52.78 (range 16.56–106.6) |
| HbA1c (%) at diagnosis | |
| <8.7 | 4/6 |
| >8.7 | 2/6 |
| Autoantibody positivity (n) | |
| GADA | 2/6 performed |
| ZnT8 | 0/0 performed |
| IA2 | 1/4 performed |
| Anti-insulin | 1/3 performed |
| Total | 4/7 tested patients presented positive antibodies |
| Management (n) | |
| Discontinued | 3/14 |
| Stopped and resumed | 3/14 |
| Continued | 4/14 |
| Unknown | 4/14 |
| Insulin therapy (n) | |
| Glycemia control | 12 |
| Death | 1 |
| N/A data | 1 |
| Intensive care unit | 2 |
| Evolution | |
| Glycemia control | 13/14 |
| Remission after treatment discontinuation (n) | 1/14 |
| Death | 1 |